I've got one that I'm sure I tell everyone this. It'll probably get cut because it's too It seems impossible, but I figured out jet lag. You have figured out.I swear to you, I tell me, please. Okay. I used to have such severe jet lag when I would go from east to west like back home.And I heard from someone, the trick is you don't eat on the plane and when you land, you go on a run before you eat anything. And for many, many years I didn't do it. And I finally just resorted to it. ...

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed ...

BITCOIN JUST BROKE OUT FROM THE BULLISH FLAGKEEP YOUR EYES ON THE $110K KEY LEVEL https://t.co/pOSiGD2JSr ...

BITCOIN IS BREAKING OUT FROM THE BULLISH FLAGKEEP YOUR EYES ON THE $110K KEY LEVEL https://t.co/8Qv2UsFPvg ...

7 Job Posting Red Flags You Can’t Afford To Ignore In 2025 https://t.co/qyh97e0YP2 https://t.co/qyh97e0YP2 ...

Core Viewpoint - AeroVironment's stock price is projected to reach new highs this year, supported by strong Q4 results and positive guidance, indicating a bullish market sentiment [1][2]. Financial Performance - AeroVironment reported a nearly 40% year-over-year revenue growth in Q4, with significant contributions from various segments: Loitering Munitions Systems grew by 87%, MacReady Works by 24%, and Uncrewed Systems by 8% [6]. - The company's income from operations, net income, adjusted EBITDA, and adjusted EPS all more than doubled, with adjusted EBITDA and EPS growing more than 3x and 4x, respectively [7]. Market Guidance - The guidance for FY2026 anticipates robust growth, driven by the acquisition of BlueHalo, a defense contractor focused on advanced automated systems, with expected revenue growth exceeding 135% [8]. - Bookings reached record levels in FY2025, surpassing $1.2 billion, and are expected to continue accelerating due to increased demand for automated systems amid geopolitical tensions [9]. Analyst Sentiment - Analysts have shown a bullish sentiment towards AeroVironment, with upgrades and price target increases leading up to the release, and a positive report from Stifel highlighting the company's position in next-gen defense technology [3][4]. - The stock's price forecast ranges from a low of $190 to a high of $245, with an average target of $213, indicating potential for further price appreciation [10]. Institutional Support - Institutional ownership exceeds 85%, with strong buying activity noted in Q1 and Q2 of 2025, contributing to a robust support base for the stock [10]. - Short interest reached nearly 15% ahead of the report, with short-covering contributing to the stock's price rise [10].

We all wear a mask. Some of us just wear so many we forget our real face. Let me show you mine.Who is it. Come in. Hey, Mommy's Princess.Yes, you can get a snack. Close mommy door behind you. Glow is not just another girls organization.We are the organization. So, if we're really going to make the impact that we say we're making, there must be measurements. You let me know when it's done.Yes, bae. No, I do not know where your glasses are. I'll be done in a minute, baby.Just like the different masks you've j ...

Core Insights - Immutep Limited's investigator-initiated EFTISARC-NEO Phase II trial has successfully met its primary endpoint, demonstrating a significant increase in tumour hyalinization/fibrosis in patients with resectable soft tissue sarcoma (STS) when treated with eftilagimod alfa (efti) combined with radiotherapy and KEYTRUDA® [1][7]. Company Overview - Immutep is a late-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases, particularly leveraging the Lymphocyte Activation Gene-3 (LAG-3) pathway [7]. - The company is pioneering the understanding and advancement of therapeutics related to LAG-3, aiming to provide novel treatment options for patients and maximize shareholder value [7]. Trial Details - The EFTISARC-NEO trial showed a median of 50% tumour hyalinization/fibrosis in a preliminary analysis of 21 patients, significantly exceeding the prespecified median of 35% [3]. - The trial is primarily funded by a grant from the Polish government, with a total enrollment of 40 patients completed in January 2025 [3][4]. Medical Significance - Tumour hyalinization/fibrosis serves as an early surrogate endpoint linked to improved overall survival and recurrence-free survival in STS patients [2]. - STS is classified as an orphan disease with a high unmet medical need and poor prognosis, with an estimated 13,520 new cases and 5,420 deaths in the U.S. in 2025 [4]. Eftilagimod Alfa (efti) Profile - Efti is a proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [5]. - Efti is under evaluation for various solid tumours, including non-small cell lung cancer and head and neck squamous cell carcinoma, and has received Fast Track designation from the FDA for certain indications [6].

First-ever bar joins LTH Rewind Collagen Elixir and LTH Prime Collagen Peptides powder in highly trusted supplement collectionCHANHASSEN, Minn., May 15, 2025 /PRNewswire/ -- Life Time (NYSE: LTH), the nation's premier healthy lifestyle brand, is going all-in on collagen. The LTH supplement lineup has unveiled its new Refuel Protein Bar as the newest addition to its offerings of collagen-rich products as more consumers explore its ability to support joint health, skin elasticity, stronger hair and more. ...

Professor Elizaveta Kon from Humanitas Research Hospital, who plans to present 4-year outcomes of the implant with respect to gender during AANA 2025, highlighted the importance of inclusivity in study design. "We need a technology that we can trust to work in the patients we see day-to-day. This is where CARTIHEAL has excelled, showcasing superior performance across genders, lesion location, and more." Dr. Vinod Dasa of Louisiana State University School of Medicine finds the technology particularly meaning ...